Abstract
BIRC3 is a recurrently mutated gene in chronic lymphocytic leukemia (CLL) but the functional implications of BIRC3 mutations are largely unexplored. Furthermore, little is known about the prognostic impact of BIRC3 mutations in CLL cohorts homogeneously treated with first-line fludarabine, cyclophosphamide, and rituximab (FCR). By immunoblotting analysis, we showed that the non-canonical nuclear factor-κB pathway is active in BIRC3-mutated cell lines and in primary CLL samples, as documented by the stabilization of MAP3K14 and by the nuclear localization of p52. In addition, BIRC3-mutated primary CLL cells are less sensitive to flu-darabine. In order to confirm in patients that BIRC3 mutations confer resistance to fludarabine-based chemoimmunotherapy, a retrospective multicenter cohort of 287 untreated patients receiving first-line FCR was analyzed by targeted next-generation sequencing of 24 recurrently mutated genes in CLL. By univariate analysis adjusted for multiple comparisons BIRC3 mutations identify a poor prognostic subgroup of patients in whom FCR treatment fails (median progression-free survival: 2.2 years, P<0.001) similar to cases harboring TP53 mutations (median progression-free survival: 2.6 years, P<0.0001). BIRC...Continue Reading
Citations
May 28, 2020·Cancers·Bhawana GeorgeNeeraj Jain
Jul 17, 2020·Expert Review of Hematology·Tsering Gyalpo LamaSusan O'Brien
Sep 29, 2020·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Arnon P KaterJohn F Seymour
Sep 11, 2019·International Journal of Molecular Sciences·Pavel Klener
Mar 14, 2020·Cancers·Riccardo MoiaGianluca Gaidano
Mar 19, 2020·Cancers·Giacomo AndreaniAlessandro Morotti
Nov 28, 2019·Expert Review of Hematology·Riccardo MoiaGianluca Gaidano
Oct 6, 2020·Expert Opinion on Therapeutic Targets·Riccardo MoiaGianluca Gaidano
Oct 25, 2020·Cancer Medicine·Linzhi HanConghua Xie
Jan 8, 2021·Leukemia & Lymphoma·Paul J HampelTimothy G Call
Oct 16, 2020·Haematologica·Andrea Patriarca, Gianluca Gaidano
Jan 9, 2021·Cell & Bioscience·Raffaele Frazzi
Mar 9, 2021·Pathology·Anya K HotinskiBryone J Kuss
Mar 14, 2021·American Journal of Clinical Pathology·Audrey N JajoskyHoward J Meyerson
May 10, 2020·Haematologica·Thomas LewisChris Pepper
Jul 3, 2021·Cancers·Irene López-OrejaDolors Colomer
Jun 28, 2021·Hematology/oncology Clinics of North America·Shanmugapriya Thangavadivel, Jennifer A Woyach
Jul 11, 2021·Blood Cancer Journal·Miguel Quijada-ÁlamoJesús-María Hernández-Rivas
Mar 9, 2021·Blood·Gerben DunsChristian Steidl
Jul 23, 2021·British Journal of Haematology·Riccardo MoiaGianluca Gaidano
Aug 17, 2021·The Cancer Journal·Riccardo MoiaGianluca Gaidano
Aug 22, 2021·Leukemia·Selcen ÖztürkMartina Seiffert
Aug 28, 2021·Journal of Clinical Medicine·Maciej Putowski, Krzysztof Giannopoulos
Jul 3, 2020·The Journal of Molecular Diagnostics : JMD·Jimmy Lee, Y Lynn Wang
Jul 29, 2021·Blood·Deborah M Stephens, John C Byrd
Nov 19, 2021·Cancer Medicine·David E SpanerYonghong Shi